Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06628921
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-03
Brief Title:
The Effectiveness of Eptinezumab During a Migraine Attack the BE-FREE Study a TACHIS Sub-study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effectiveness of Eptinezumab During a Migraine Attack the BE-FREE Study a TACHIS Sub-study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BEFREE
Brief Summary:
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack During the intravenous infusion of eptinezumab some patients experiencing an ongoing migraine attack report its resolution This finding is known in the literature having been described in the RELIEF study This study was designed to also evaluate in a real-world setting the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved
The study includes all patients who will begin treatment according to clinical practice and are included in the TACHIS study NCT06409845 Unique protocol ID RICe_5
The study includes all patients who will begin treatment according to clinical practice and are included in the TACHIS study NCT06409845 Unique protocol ID RICe_5
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None